Latest Intellia Therapeutics News & Updates

See the latest news and media coverage for Intellia. We track all announcements, press releases, and industry mentions in real time, all in one place.

Intellia Therapeutics (Intellia)

Clinical-stage genome editing company

intelliatx.com

Headquarters: Cambridge, United States
Founded year: 2014
Company type: Public company
Number of employees: 500–540
Industry: Pharmaceuticals

Last updated Today

Latest news about Intellia Therapeutics (Intellia)

In short: Intellia secured FDA priority review for its HAE gene therapy lonvo-z and reported strong Phase 3 results.

Company announcements

Today Intellia

Intellia announces lonvo-z investor event and ACAAI presentations

The company will present seven studies on Hereditary Angioedema at the conference and host a webcast to discuss commercial launch preparations.

October 13 Intellia

Intellia welcomes Jing Marantz as Chief Medical Officer

Marantz joins with extensive experience in rare disease therapies, bringing clinical and approval expertise to support the company's mission.

September 8 Intellia

Intellia announces FDA acceptance for hereditary angioedema therapy

The agency grants priority review and sets a PDUFA target date of March 10, 2027. Phase 3 data showed significant attack reduction.

July 30 Intellia

Intellia announces Q2 2026 financial results and business updates

The company highlighted positive Phase 3 HAELO results for lonvo-z, anticipates FDA BLA acceptance in H2 2026, and ended Q2 with $628 million cash.

Media coverage

October 5 Benzinga

Intellia Therapeutics Options

View Intellia Therapeutics (NTLA) options chain, put/call ratios, volume and open interest data.

September 23 Yahoo Finance

CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?

CRSP shares closed down 6% on Wednesday, while PRME and EDIT stocks declined 12% and 8%,...

September 18 Healio

FDA grants priority review to lonvoguran ziclumeran for hereditary angioedema

The FDA has accepted Intellia Therapeutics' biologics license application for lonvoguran ziclumeran for treating hereditary angioedema and granted priority review, according to a press release.Notably...

September 8 The Globe and Mail

Intellia's Lonvo-z Gains FDA Priority Review for HAE

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

Never miss news about Intellia

Track Intellia and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Intellia competitors & trending companies

Browse news for competitors to Intellia and other trending companies.